Lancet PsychiatryPub Date : 2025-04-15DOI: 10.1016/s2215-0366(25)00090-2
Ellie M Robson, Susan M Sawyer
{"title":"Accurate prevalence estimates needed for youth common mental disorders – Authors' reply","authors":"Ellie M Robson, Susan M Sawyer","doi":"10.1016/s2215-0366(25)00090-2","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00090-2","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"66 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143836863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lancet PsychiatryPub Date : 2025-04-15DOI: 10.1016/s2215-0366(25)00086-0
{"title":"Correction to Lancet Psychiatry 2025; 12: e3–6","authors":"","doi":"10.1016/s2215-0366(25)00086-0","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00086-0","url":null,"abstract":"<em>The Lancet Psychiatry. Thanks to our peer reviewers for 2024</em>. The Lancet Psychiatry <em>2025; <strong>12:</strong> e3–6</em>—In this Comment, Ángel Aguilera Martín should have been included in the list of peer reviewers for 2024. This correction has been made to the online version as of April 15, 2025.","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"40 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143837158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lancet PsychiatryPub Date : 2025-04-15DOI: 10.1016/s2215-0366(25)00095-1
Vivian B Pender
{"title":"Priovi appears to be a valuable digital tool for patients with borderline personality disorder","authors":"Vivian B Pender","doi":"10.1016/s2215-0366(25)00095-1","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00095-1","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"108 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143836861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lancet PsychiatryPub Date : 2025-04-15DOI: 10.1016/s2215-0366(25)00103-8
{"title":"Setting the research agenda for mental health","authors":"","doi":"10.1016/s2215-0366(25)00103-8","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00103-8","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"6 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143836860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lancet PsychiatryPub Date : 2025-04-15DOI: 10.1016/s2215-0366(25)00042-2
Patrick D McGorry, Eóin Killackey, Eric Chen, Andrew Chanen
{"title":"Accurate prevalence estimates needed for youth common mental disorders","authors":"Patrick D McGorry, Eóin Killackey, Eric Chen, Andrew Chanen","doi":"10.1016/s2215-0366(25)00042-2","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00042-2","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"40 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143836862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lancet PsychiatryPub Date : 2025-04-10DOI: 10.1016/s2215-0366(25)00061-6
Elise Koch, Sophie Smart, Guðmundur Einarsson, Anders Kämpe, Lina Jonsson, Maris Alver, Matthew Iveson, Andreas Göteson, Antonio F Pardiñas, Ida E Sønderby, Kevin S O'Connell, Qingqin Li, Yi Lu, Hreinn Stefánsson, Kári Stefánsson, Heather Whalley, Mikael Landén, Michael C O'Donovan, Knut Smerud, Gerard R Dawson, Ole A Andreassen
{"title":"Recommendations for defining treatment outcomes in major psychiatric disorders using real-world data","authors":"Elise Koch, Sophie Smart, Guðmundur Einarsson, Anders Kämpe, Lina Jonsson, Maris Alver, Matthew Iveson, Andreas Göteson, Antonio F Pardiñas, Ida E Sønderby, Kevin S O'Connell, Qingqin Li, Yi Lu, Hreinn Stefánsson, Kári Stefánsson, Heather Whalley, Mikael Landén, Michael C O'Donovan, Knut Smerud, Gerard R Dawson, Ole A Andreassen","doi":"10.1016/s2215-0366(25)00061-6","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00061-6","url":null,"abstract":"Although information from real-world data can be used to identify factors that aid treatment choice, there are no guidelines for the use of such data. The aim of this Review is to summarise and evaluate definitions of treatment outcomes for antidepressants, antipsychotics, and mood stabilisers when using real-world data, and to suggest standards for the field. Given that no standards for the use of these data in estimating treatment outcomes exist, variability is high for treatment outcome definitions. We make recommendations for different scenarios of available data and highlight the importance of using other sources of information to validate proxy measures such as continued treatment, switching between medications, or polypharmacy of psychotropic medications. Well defined and validated treatment outcome measures that incorporate real-world data could facilitate the development of precision psychiatry approaches and support regulatory decision making regarding psychopharmacological agents.","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"108 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143820079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lancet PsychiatryPub Date : 2025-04-08DOI: 10.1016/s2215-0366(25)00044-6
Linda Theron, Dov J Stekel, Jan Höltge, Olufunmilayo I Fawole, Diane T Levine, Zainab Mai-Bornu, Kassa Maksudi, Olanrewaju Olaniyan, Caradee Y Wright, Michael Ungar
{"title":"Factors that affect the resilience of young adults to depression: a systematic review","authors":"Linda Theron, Dov J Stekel, Jan Höltge, Olufunmilayo I Fawole, Diane T Levine, Zainab Mai-Bornu, Kassa Maksudi, Olanrewaju Olaniyan, Caradee Y Wright, Michael Ungar","doi":"10.1016/s2215-0366(25)00044-6","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00044-6","url":null,"abstract":"Depression among young people (aged 18–29 years) transitioning to adulthood is becoming more widespread. Knowing which factors in which systems co-enable resilience to depression is crucial, but there is no comprehensive synthesis of the physiological, psychological, social, economic, institutional, cultural, and environmental system factors associated with no or minimal emerging adult depression, or combinations of these factors. We have therefore conducted a preregistered systematic review (Prospero, CRD42023440153). We searched eight databases for observational studies reporting factors associated with depression symptomology that is mild, minimal, or absent among emerging adults with exposure to risk factors for depression; independently screened titles, abstracts, and full texts; extracted data; and assessed study quality. From 1824 unique citations, we included 139 papers (N=17721; in study populations that are majority female, cisgender, and in North America) and conducted a multisystemic resilience-informed narrative synthesis and quantitative summary. Personal (eg, psychological resilience and positive cognition) or social factors (eg, social support and family support) were frequently linked to reduced depression symptomology, followed by combinations of these. Economic, institutional, cultural, and environmental factors, or combinations of factors from three or more systems, were rarely reported. Low-income and middle-income countries, in which most young people live, were under-represented, which suggests inadequate understanding of emerging adult resilience to depression. Future studies should include more diverse populations and redress the tendency to reduce resilience to depression to a psychological or limited social phenomenon.","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"16 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143806248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lancet PsychiatryPub Date : 2025-04-07DOI: 10.1016/s2215-0366(25)00043-4
Caroline Ward, Milica Pejović Milovančević, Eva Kohegyi, Nanco Hefting, Catherine Aurang, Dalei Chen, Klaus Groes Larsen, Mary Hobart, Christoph U Correll
{"title":"Efficacy and safety of brexpiprazole in adolescents with schizophrenia: a multicountry, randomised, double-blind, placebo-controlled, phase 3 trial with an active reference","authors":"Caroline Ward, Milica Pejović Milovančević, Eva Kohegyi, Nanco Hefting, Catherine Aurang, Dalei Chen, Klaus Groes Larsen, Mary Hobart, Christoph U Correll","doi":"10.1016/s2215-0366(25)00043-4","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00043-4","url":null,"abstract":"<h3>Background</h3>New treatment options are needed for adolescent schizophrenia, partly due to an unfavourable risk–benefit profile of current options. This trial aimed to evaluate the short-term efficacy and safety of brexpiprazole in adolescents with schizophrenia.<h3>Methods</h3>This multicountry, randomised, double-blind, parallel-arm, placebo-controlled, phase 3 trial with an active reference was done at 62 outpatient sites in ten countries. Eligible patients were aged 13–17 years with a primary DSM-5 diagnosis of schizophrenia and a Positive and Negative Syndrome Scale (PANSS) total score ≥80 at screening and baseline. Patients were randomly assigned (1:1:1) to oral brexpiprazole 2–4 mg/day, placebo, or aripiprazole 10–20 mg/day (active reference). Patients, investigators, and sponsor personnel were masked to treatment assignment. The primary efficacy endpoint was change from baseline to week 6 in PANSS total score (in randomly assigned patients who took at least one dose of study drug and had baseline and post-baseline PANSS evaluations). Safety was assessed in randomly assigned patients who took at least one dose of study drug. People with lived experience of schizophrenia were not involved in the research or writing process. The trial was registered with <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, <span><span>NCT03198078</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, and is complete.<h3>Findings</h3>Between June 29, 2017, and Feb 23, 2023, 376 patients were screened, and 316 patients were randomly assigned to brexpiprazole (n=110), placebo (n=104), or aripiprazole (n=102). The mean age of patients was 15·3 years (SD 1·5). 166 (53%) of 316 patients were female and 150 (47%) were male. Of 316 patients, seven (2%) were American Indian or Alaskan Native, two (1%) were Asian, 21 (7%) were Black or African American, 204 (65%) were White, and 81 (26%) were other, as reported using US Census Bureau classifications. Mean doses of brexpiprazole and aripiprazole at last visit were 3·0 mg (SD 0·9) and 13·9 mg (4·7), respectively. Least squares mean change from baseline to week 6 in PANSS total score was –22·8 (SE 1·5) with brexpiprazole and –17·4 (1·6) with placebo (least squares mean difference –5·33 [95% CI –9·55 to –1·10]; p=0·014). The corresponding PANSS total score change at week 6 with aripiprazole was –24·0 (SE 1·6; least squares mean difference versus placebo –6·53 [95% CI –10·8 to –2·21]; p<sub>nominal</sub>=0·0032, not adjusted for multiple testing). Treatment-emergent adverse events were reported in 44 (40%) of 110 patients in the brexpiprazole group, 42 (40%) of 104 in the pla","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"23 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143798094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lancet PsychiatryPub Date : 2025-04-07DOI: 10.1016/s2215-0366(25)00094-x
Maria Rogdaki
{"title":"Brexpiprazole for the treatment of adolescent schizophrenia","authors":"Maria Rogdaki","doi":"10.1016/s2215-0366(25)00094-x","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00094-x","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"74 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143798093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}